2 165

Cited 22 times in

Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea

 Hee Young Shin  ;  Hyoung Jin Kang  ;  Eun Sil Park  ;  Hyoung Soo Choi  ;  Hyo Seop Ahn  ;  Sun Young Kim  ;  Nak Gyun Chung  ;  Hack Ki Kim  ;  So Youn Kim  ;  Hoon Kook  ;  Tai Ju Hwang  ;  Kwang Chul Lee  ;  Sun Min Lee  ;  Kun Soo Lee  ;  Keon Hee Yoo  ;  Hong Hoe Koo  ;  Mee Jung Lee  ;  Jong Jin Seo  ;  Hyung Nam Moon  ;  Thad Ghim  ;  Chuhl Joo Lyu  ;  Won Sik Lee  ;  Yong Mook Choi 
 PEDIATRIC BLOOD & CANCER, Vol.46(4) : 439-445, 2006 
Journal Title
Issue Date
Adolescent ; Child ; Child, Preschool ; Drug Administration Schedule ; Female ; Hematologic Neoplasms/complications* ; Humans ; Hyperuricemia/complications* ; Hyperuricemia/drug therapy* ; Infant ; Infant, Newborn ; Korea/epidemiology ; Male ; Prospective Studies ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/therapeutic use ; Renal Dialysis ; Treatment Outcome ; Urate Oxidase/administration & dosage ; Urate Oxidase/adverse effects ; Urate Oxidase/therapeutic use* ; Uric Acid/blood
compassionate study ; hematologic malignancy ; hyperuricemia ; pediatric patients ; rasburicase tumor lysis syndrome
BACKGROUND: Hyperuricemia accompanying tumor lysis syndrome is a serious complication in neoplasia with rapid proliferation and destruction. To confirm the efficacy of recombinant urate oxidase (rasburicase) and its safety profile, a phase IV compassionate use prospective study was performed in Korean pediatric patients with hematologic malignancies. PROCEDURE: Rasburicase was administered at 0.2 mg/kg/day once daily for 3-5 days (twice daily allowed during the first 72 hr) by intravenous route for hyperuricemia (uric acid > 7.5 mg/dl). The study period was 5 weeks and consisted of a baseline assessment within 48 hr before the administration of rasburicase, 3-5 days of assessment during treatment and a follow-up assessment at 4 weeks after its final administration. RESULTS: The uric acid endpoint (< or =7.0 mg/dl) was reached in 97.3% (36/37) of the patients and uric acid levels were significantly reduced in all patients (P < 0.001). Drug related toxicities were mild and reversible without any grade 4 or serious adverse event associated with rasburicase. CONCLUSION: This study confirms that rasburicase is a safe and effective agent for the treatment of hyperuricemia associated with hematologic malignancies in pediatric patients.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
Lyu, Chuhl Joo(유철주) ORCID logo https://orcid.org/0000-0001-7124-7818
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.